Structural insights into μ-opioid receptor activation

Nature

Volumn 524, Issue 7565, 2015, Pages 315-321

  Huang, Weijiao ^a   Manglik, Aashish ^a   Venkatakrishnan, A J ^a,b   Laeremans, Toon ^c,d   Feinberg, Evan N ^a,b   Sanborn, Adrian L ^a,b   Kato, Hideaki E ^a   Livingston, Kathryn E ^e   Thorsen, Thor S ^a   Kling, Ralf C ^f   Granier, Sébastien ^g   Gmeiner, Peter ^f   Husbands, Stephen M ^h   Traynor, John R ^e   Weis, William I ^a   Steyaert, Jan ^c,d   Dror, Ron O ^a,b   Kobilka, Brian K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIV MONTPELLIER   (France)

^h University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BETA 2 ADRENERGIC RECEPTOR; BU 72; G PROTEIN COUPLED RECEPTOR; MORPHINAN DERIVATIVE; MU OPIATE RECEPTOR; MUSCARINIC M2 RECEPTOR; NANOBODY; UNCLASSIFIED DRUG; BU72 COMPOUND; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PYRROLE DERIVATIVE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID; ANTIBODY; CYTOPLASM; FRAGMENTATION; LIGAND; MOLECULAR ANALYSIS; NUMERICAL MODEL; PROTEIN; STABILIZATION;

ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; LIGAND BINDING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; AGONISTS; ALLOSTERISM; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CAMELIDAE; MURINAE;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HETEROTRIMERIC GTP-BINDING PROTEINS; MICE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MORPHINANS; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PYRROLES; RECEPTOR, MUSCARINIC M2; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, OPIOID, MU; SINGLE-CHAIN ANTIBODIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939795137     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14886     Document Type: Article

References (66)

1. Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the m-opioid-receptor gene. Nature 383, 819-823 (1996).
2. Brownstein, M. J. A brief history of opiates, opioid peptides, and opioid receptors. Proc. Natl Acad. Sci. USA 90, 5391-5393 (1993).
3. Schumacher, M. A., Basbaum, A. I. & Naidu, R. K., (McGraw-Hill Medical, 2015).
4. Raehal, K. M., Walker, J. K. & Bohn, L. M. Morphine side effects in b-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 314, 1195-1201 (2005).
5. Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J. & Caron, M. G. m-Opioid receptor desensitization by b-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720-723 (2000).
6. Bohn, L. M. et al. Enhanced morphine analgesia in mice lacking b-arrestin 2. Science 286, 2495-2498 (1999).
7. Pasternak,G.W.&Pan, Y.-X.Muopioids andtheir receptors: evolution of a concept. Pharmacol. Rev. 65, 1257-1317 (2013).
8. Chavkin, C. & Goldstein, A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc. Natl Acad. Sci. USA 78, 6543-6547 (1981).
9. Manglik, A. et al. Crystal structure of the m-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326 (2012).
10. Granier, S. et al. Structure of the d-opioid receptor bound to naltrindole. Nature 485, 400-404 (2012).
11. Fenalti, G. et al. Molecular control of d-opioid receptor signalling. Nature 506, 191-196 (2014).
12. Rasmussen, S. G. F. et al. Structure of a nanobody-stabilized active state of the b2 adrenoceptor. Nature 469, 175-180 (2011).
13. Ring, A. M. et al. Adrenaline-activated structure of b2-adrenoceptor stabilized by an engineered nanobody. Nature 502, 575-579 (2013).
14. Cherezov, V. et al. High-resolution crystal structure of an engineered human b2-adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007).
15. Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into b2-adrenergic receptor function. Science 318, 1266-1273 (2007).
16. Haga, K. et al. Structure of the humanM2muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012).
17. Kruse, A.C. et al. Activation and allostericmodulation of amuscarinic acetylcholine receptor. Nature 504, 101-106 (2013).
18. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745 (2000).
19. Choe, H.-W. et al. Crystal structure of metarhodopsin II. Nature 471, 651-655 (2011).
20. Rosenbaum, D. M. et al. Structure and function of an irreversible agonist-b2 adrenoceptor complex. Nature 469, 236-240 (2011).
21. Nygaard, R. et al. The dynamic process of b2-adrenergic receptor activation. Cell 152, 532-542 (2013).
22. Manglik, A. & Kobilka, B. The role of protein dynamics in GPCR function: insights from the b2AR and rhodopsin. Curr. Opin. Cell Biol. 27, 136-143 (2014).
23. Manglik, A. et al. Structural insights into the dynamic process of b2-adrenergic receptor signaling. Cell 161, 1101-1111 (2015).
24. De Lean, A., Stadel, J. M. & Lefkowitz, R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled b-adrenergic receptor. J. Biol. Chem. 255, 7108-7117 (1980).
25. Rasmussen,S.G. F. et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
26. Schiller, P. W. et al. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 35, 895-901 (2000).
27. Neilan, C. L. et al. Characterization of the complexmorphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur. J. Pharmacol. 499, 107-116 (2004).
28. Caffrey, M. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. Annu. Rev. Biophys. 38, 29-51 (2009).
29. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of threedimensionalmodels and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995).
30. Wu, H. et al. Structure of the human k-opioid receptor in complex with JDTic. Nature 485, 327-332 (2012).
31. Sounier, R. et al. Propagation of conformational changes during m-opioid receptor activation. Nature http://dx.doi.org/10.1038/nature14680 (2015).
32. Chaturvedi, K., Shahrestanifar, M. & Howells, R. D. m Opioid receptor: role for the amino terminus as a determinant of ligand binding affinity. Brain Res. Mol. Brain Res. 76, 64-72 (2000).
33. Gales, C. et al. Probing the activation-promoted structural rearrangements in preassembled receptor-Gprotein complexes.Nature Struct.Mol.Biol. 13, 778-786 (2006).
34. Husbands, S. M. et al. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur. J. Pharmacol. 509, 117-125 (2005).
35. Takemori, A. E., Larson, D. L. & Portoghese, P. S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur. J. Pharmacol. 70, 445-451 (1981).
36. Zhang, C. et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387-392 (2012).
37. Liu, W. et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337, 232-236 (2012).
38. Miller-Gallacher, J. L. et al. The 2.1A° resolution structure of cyanopindolol-bound b1-adrenoceptor identifies an intramembrane Na1 ion that stabilises the ligandfree receptor. PLoS ONE 9, e92727 (2014).
39. Pert, C. B., Pasternak, G. & Snyder, S. H. Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182, 1359-1361 (1973).
40. Manglik, A. et al. Structural insights into the dynamic process of b2-adrenergic receptor signaling. Cell 161, 1101-1111 (2015).
41. Park, J. H.,Scheerer, P.,Hofmann,K.P.,Choe, H. W.&Ernst,O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-187 (2008).
42. Knierim,B., Hofmann, K. P.,Gartner,W., Hubbell, W. L.&Ernst,O.P.Rhodopsin and 9-demethyl-retinal analog: effect of a partial agonist on displacement of transmembrane helix 6 in class A G protein-coupled receptors. J. Biol. Chem. 283, 4967-4974 (2008).
43. Pardon, E. et al. A general protocol for the generation of nanobodies for structural biology. Nature Protocols 9, 674-693 (2014).
44. Whorton, M. R. et al. A monomeric G protein-coupled receptor isolated in a highdensity lipoprotein particle efficiently activates its G protein. Proc. Natl Acad. Sci. USA 104, 7682-7687 (2007).
45. Kuszak, A. J. et al. Purification and functional reconstitution of monomeric muopioid receptors: allosteric modulation of agonist binding by Gi2. J. Biol. Chem. 284, 26732-26741 (2009).
46. Motulsky, H. J. & Mahan, L. C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 1-9 (1984).
47. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
48. Kabsch, W. XDS. Acta Crystallogr. D 66, 125-132 (2010).
49. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658-674 (2007).
50. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
51. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352-367 (2012).
52. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).
53. Lomize, M. A., Lomize, A. L., Pogozheva, I. D. & Mosberg, H. I. OPM: orientations of proteins in membranes database. Bioinformatics 22, 623-625 (2006).
54. Brooks, B. R. et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 30, 1545-1614 (2009).
55. Jo, S., Kim, T. & Im, W. Automated builder and database of protein/membrane complexes for molecular dynamics simulations. PLoS ONE 2, e880 (2007).
56. Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859-1865 (2008).
57. Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997-2004 (2014).
58. Case, D. A. et al. AMBER 14. (University of California, San Francisco, 2014).
59. Le Grand, S., Götz, A. W. & Walker, R. C. SPFP: Speed without compromise - A mixed precision model for GPU accelerated molecular dynamics simulations. Comput. Phys. Commun. 184, 374-380 (2013).
60. Salomon-Ferrer, R., Götz, A. W., Poole, D., Le Grand, S. & Walker, R. C. Routine microsecond molecular dynamics simulations with Amber on GPUs. 2 Explicit solvent particle mesh Ewald. J. Chem. Theory Comput. 9, 3878-3888 (2013).
61. Best, R. B. et al. Optimization of the additive CHARMM all-atomprotein force field targeting improved sampling of the backbone w, y and side-chain x1 and x2 dihedral angles. J. Chem. Theory Comput. 8, 3257-3273 (2012).
62. Klauda, J. B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830-7843 (2010).
63. MacKerell, A. D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616 (1998).
64. Mackerell, A. D., Feig, M. & Brooks, C. L. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantummechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 25, 1400-1415 (2004).
65. Vanommeslaeghe, K. et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atomadditive biological force fields. J. Comput. Chem. 31, 671-690 (2010).
66. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38 (1996).